RXST at a glance
RxSight, Inc. (RXST, SEC CIK 1111485) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 3, 2026 and Form 4 insider filings as recently as September 16, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), RxSight, Inc. (RXST) reported revenue of $134.5 million (down 3.9% from FY2024) and a net loss of $38.9 million. Diluted EPS was -$0.95.
- As of September 30, 2026, 24 institutional investment managers tracked by SignalX reported holding RxSight, Inc. (RXST) shares worth $87.2 million in 13F-HR filings.
- In the last 90 days, RXST insiders reported 0 open-market purchases ($0) and 4 open-market sales ($118K) on Form 4, a net sale of $118K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $134.5M
- −3.9% vs prior year
- Insiders · 90 days
- 0 buys · 4 sells
- Net −$118K
- 13F holders
- 24 funds
- $87.2M · −1 vs prior quarter
- Latest 8-K
- Nov 3, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Q3 revenue $24.6M, down 19.0% YoY from $30.3M, amid increased IOL competition
- Product gross margin 73.6% vs 79.9% YoY, pressured by inventory reserves and higher-cost inventory
- LAL sales $22.8M vs $25.7M YoY, while LDD sales fell to $3.2M from $4.1M
- Cash, equivalents and short-term investments $254.7M; operating cash flow $24.8M vs $(14.4)M YoY
- Near-term outlook: renewed revenue growth expected from commercial realignment, with competitive trialing and excess LDD inventory as headwinds
Risk Factors
- New risk from June 2026 Alcon collaboration: $70M feasibility and $40M approval milestones remain optional and contingent
- Most material update: LDD manufacturing paused in Q3 2026 after declining sales, creating inventory write-down and margin risks
- Regulatory risk: QMSR became effective February 2026, requiring compliant manufacturing processes for continued commercialization
- Near-term market risk: sales declined through Q3 2026, while premium LAL demand remains sensitive to patient out-of-pocket spending
- Financial risk: $254.7M cash, equivalents and short-term investments held with one financial institution as of September 30, 2026
AI summary of the RXST 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 results announcement for the three months ended September 30, 2026
- Detailed financial results and operating metrics available in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q3 revenue $24.6M, down 19% YoY, signaling intensified competitive pressure and weaker near-term demand
- LAL volume 23,128 units, while Alcon collaboration revenue was only $40K during the quarter
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results announced for the three months ended June 30, 2026
- Press release Exhibit 99.1 contains the financial results and operating details relevant to investors
Item EX-99.1: Item EX-99.1
- Q2 revenue $33.7M, including $6.5M Alcon collaboration revenue; product sales fell 19% to $27.2M
- Product gross margin declined to 71.2% from 74.9%; total margin reached 76.7% with collaboration revenue
Item 5.02: Departure/Appointment of Directors or Principal Officers
- CEO transition effective July 20, 2026: Aziz Mottiwala replaces Ron Kurtz, who becomes Chief Medical Officer after leading since 2016
- Mottiwala brings commercial leadership from Tarsus, Opiant, Avanir, and Allergan, potentially emphasizing commercialization execution
Item EX-99.1: Item EX-99.1
- Leadership transition effective July 20, 2026, with Aziz Mottiwala becoming President and CEO
- Ron Kurtz, M.D. moving to Chief Medical Officer, preserving founder-level product and clinical expertise
Item 7.01: Regulation FD Disclosure
- Mottiwala appointed President and CEO, signaling leadership transition at RxSight
- Dr. Kurtz transitions to Chief Medical Officer, retaining a senior medical leadership role
AI summaries of RXST 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for RXST
Don't miss the next RXST filing
- Alerts as it files. A push when RXST files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut RXST, by share count.
- Ask anything. An AI agent that reads every RXST filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Weinberg Eric | M | Sep 15, 2026 | 35,168 | $4.34 |
| Weinberg Eric | M | Sep 15, 2026 | 35,168 | - |
| Weinberg Eric | A | Sep 5, 2026 | 82,608 | - |
| Weinberg Eric | D | Sep 5, 2026 | 125,000 | - |
| Weinberg Eric | D | Sep 5, 2026 | 92,200 | - |
| Weinberg Eric | D | Sep 5, 2026 | 95,000 | - |
| Weinberg Eric | D | Sep 5, 2026 | 87,437 | - |
| Wilterding Mark | D | Sep 5, 2026 | 258,770 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $139.9M | $134.5M |
| Gross Profit | - | $98.9M | $103.0M |
| Operating Income | - | -$36.9M | -$48.2M |
| Net Income | - | -$27.5M | -$38.9M |
| Gross Margin | - | 70.7% | 76.6% |
| Op. Margin | - | -26.3% | -35.8% |
| Net Margin | - | -19.6% | -29.0% |
| Balance Sheet | |||
| Total Assets | $182.6M | $318.6M | $311.8M |
| Equity | $160.4M | $281.2M | $275.7M |
| ROE | - | -9.8% | -14.1% |
| Per Share | |||
| EPS | - | $-0.71 | $-0.95 |
| Cash Flow | |||
| Operating CF | - | -$16.9M | -$15.5M |
| CapEx | - | $5.4M | $3.8M |
Source: XBRL data in RxSight, Inc. (RXST)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate RXST share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 24 | $87.2M |
| Q2 2026 | 25 | $93.7M |
| Q1 2026 | 26 | $102.9M |
| Q4 2025 | 22 | $157.1M |
| Q3 2025 | 23 | $135.0M |
| Q2 2025 | 24 | $170.3M |
| Q1 2025 | 23 | $262.7M |
| Q4 2024 | 19 | $289.9M |
- BlackRock+552.2K (+10%)
- Renaissance Technologies LLC+86.3K (+61%)
- Ameriprise Financial+77.3K (+119%)
- Goldman Sachs Group+67.1K (+12%)
- Dimensional Fund Advisors+51.1K (+66%)
- Millennium Management−888.2K (-29%)
- Citadel Advisors LLC−442.1K (-63%)
- Bank of America Corp−371.6K (-77%)
- AQR Capital Management−360.8K (-24%)
- Two Sigma Investments−228.8K (-20%)
- Prudential Financial+16.7K
Source: 13F-HR filings on SEC EDGAR (aggregated from 186 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
RXST filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Nov 3, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 3, 2026 | - | Analysis | - |
| 4 | Sep 16, 2026 | - | - | - |
| 4 | Sep 9, 2026 | - | - | - |
| 4 | Sep 9, 2026 | - | - | - |
| 4 | Sep 9, 2026 | - | - | - |
| 4 | Sep 9, 2026 | - | - | - |
| 4 | Sep 2, 2026 | - | - | - |
| 4 | Sep 2, 2026 | - | - | - |
| 4 | Sep 2, 2026 | - | - | - |
| 4 | Sep 2, 2026 | - | - | - |
| SC 13G | Aug 19, 2026 | - | - | |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jul 24, 2026 | - | - | - |
| SC 13G | Jul 17, 2026 | - | - | |
| 8-K | Jul 15, 2026 | - | Analysis | - |
| 8-K | Jul 6, 2026 | - | Analysis | - |
| 8-K | Jul 6, 2026 | - | Analysis | - |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
Related Health Care companies
- BLCO · Bausch & Lomb CorpOphthalmic Goods
- COO · Cooper Companies (The)Ophthalmic Goods
- EYE · National Vision Holdings, Inc.Ophthalmic Goods
- STAA · STAAR SURGICAL COOphthalmic Goods
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
RXST SEC filings: frequently asked questions
Are RXST insiders buying or selling?
In the last 90 days, RxSight, Inc. (RXST) officers, directors and 10% owners reported no open-market purchases and 4 open-market sales worth $117,951 by 4 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold RXST stock?
As of September 30, 2026, the largest RxSight, Inc. (RXST) holders among the 13F filers tracked by SignalX were BlackRock ($31.1 million), Millennium Management ($10.5 million), D.E. Shaw & Co ($9.3 million), Vanguard Capital Management LLC ($8.2 million), AQR Capital Management ($5.7 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was RXST's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), RxSight, Inc. (RXST) reported revenue of $134.5 million (down 3.9% from FY2024) and a net loss of $38.9 million. Diluted EPS was -$0.95. The figures come from the XBRL data in the 10-K.
What did RXST report in its latest 8-K?
RxSight, Inc. (RXST) filed an 8-K on November 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 results announcement for the three months ended September 30, 2026.
What are the latest RXST SEC filings?
RxSight, Inc. (RXST) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 3, 2026 and a Form 4 insider filing on September 16, 2026.
What is RXST's SEC CIK number?
RxSight, Inc. (RXST)'s SEC Central Index Key (CIK) is 1111485. EDGAR lists every RXST filing under that number.
Ask anything about RXST
The research agent reads RXST's filings, financials, insider trades and 13F holders, then answers with sources.